TABLE 1.
Type | Inhibitors | Crystal structure of BET protein | PDB code of other targets | Clinical phase | NCT identifiera | |||
---|---|---|---|---|---|---|---|---|
PDB code | Positions | Released date | Resolution (Å) | |||||
BET small-molecule inhibitors | JQ1 | 3MXF15 | 42–168 | 2010.10.06 | 1.60 | NA | NA | NA |
I-BET762 | 3P5O26 | 44–168 | 2010.11.17 | 1.60 | NA | II | NCT01943851 | |
I-BET151 | 3ZYU6 | 44–168 | 2011.11.02 | 1.50 | NA | NA | NA | |
CPI-0610 | 5HLS27 | 42–168 | 2016.02.10 | 2.18 | NA | I | NCT02157636 NCT01949883 | |
PFI-1 | 4E9628 | 44–168 | 2012.04.18 | 1.92 | NA | NA | NA | |
I-BET726 | 4BJX29 | 44–168 | 2013.10.02 | 1.59 | NA | NA | NA | |
RVX-208 | 4MR630 | 346–455 | 2013.11.27 | 1.67 | NA | III | NCT02586155 | |
ABBV-744 | 6E6J31 | 348–455 | 2019.07.31 | 2.44 | NA | I | NCT03360006 | |
BET dual-target inhibitors | Dinaciclib | 4O7032 | 44–168 | 2014.03.05 | 1.55 | 4KD133 | III | NCT01580228 |
Flavopiridol | 4O7132 | 44–168 | 2014.03.05 | 1.36 | 3BLR34 | II | NCT00023894, NCT00464633, NCT00003256 | |
BI-2536 | 4O7435 | 44–168 | 2014.02.26 | 1.73 | 2RKU36 | II | NCT00701766, NCT00376623, NCT00706498, NCT00710710 | |
TG101348 | 4OGJ35 | 44–168 | 2014.02.26 | 1.65 | NA | II | NCT04282187 | |
TG101209 | 4O7632 | 44–168 | 2014-03-05 | 1.70 | 4JI937 | NA | NA | |
SF2523 | 5U2838 | 44–180 | 2017.02.08 | 1.80 | NA | NA | NA | |
SF2558HA | 5U2C38 | 342–460 | 2017.02.08 | 3.30 | NA | NA | NA | |
SB610251B | 4O7E32 | 44–168 | 2014.03.05 | 1.85 | NA | NA | NA | |
SB202190 | 4O7732 | 44–168 | 2014.03.05 | 2.00 | NA | NA | NA | |
JWG-047 | 6CIS39 | 44–166 | 2018.08.29 | 1.51 | NA | NA | NA | |
GW612286X | 4O7832 | 44–168 | 2014.03.05 | 1.34 | 3CJF40 | NA | NA | |
NU7441 | 4O7232 | 44–168 | 2014.03.05 | 1.40 | NA | NA | NA | |
SB409514 | 4O7A32 | 44–168 | 2014.03.05 | 1.34 | NA | NA | NA | |
TW9 | 6YQN41 | 44–168 | 2020.05.06 | 1.05 | NA | NA | NA |
Abbreviation: NA, not available.
http://clinicaltrials.gov; January 2021.